Alpelisib (BYL719) ( DrugBank: Alpelisib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 138 | Nerve cell migration disorder | 1 |
138. Nerve cell migration disorder
Clinical trial : 1 / Drugs : 2 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathways : 106
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05577754 (ClinicalTrials.gov) | November 28, 2022 | 10/10/2022 | Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP) | A Phase II Double-blind Multi-center, Placebo-controlled Trial, to Assess the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP) | Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP) | Drug: Alpelisib (BYL719);Drug: Matching placebo;Procedure: Optional lumbar puncture | Centre Hospitalier Universitaire Dijon | NULL | Recruiting | 2 Years | 40 Years | All | 16 | Phase 2 | France |